» Articles » PMID: 31241444

Future Perspective of Diabetic Animal Models

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The need of today's research is to develop successful and reliable diabetic animal models for understanding the disease susceptibility and pathogenesis. Enormous success of animal models had already been acclaimed for identifying key genetic and environmental factors like Idd loci and effects of microorganisms including the gut microbiota. Furthermore, animal models had also helped in identifying many therapeutic targets and strategies for immune-intervention. In spite of a quite success, we have acknowledged that many of the discovered immunotherapies are working on animals and did not have a significant impact on human. Number of animal models were developed in the past to accelerate drug discovery pipeline. However, due to poor initial screening and assessment on inequivalent animal models, the percentage of drug candidates who succeeded during clinical trials was very low. Therefore, it is essential to bridge this gap between pre-clinical research and clinical trial by validating the existing animal models for consistency.

Results And Conclusion: In this review, we have discussed and evaluated the significance of animal models on behalf of published data on PUBMED. Amongst the most popular diabetic animal models, we have selected six animal models (e.g. BioBreeding rat, "LEW IDDM rat", "Nonobese Diabetic (NOD) mouse", "STZ RAT", "LEPR Mouse" and "Zucker Diabetic Fatty (ZDF) rat" and ranked them as per their published literature on PUBMED. Moreover, the vision and brief imagination for developing an advanced and robust diabetic model of 21st century was discussed with the theme of one miceone human concept including organs-on-chips.

Citing Articles

Menaquinone-7 and its therapeutic potential in type 2 diabetes mellitus based on a Zucker diabetic fatty rat model.

Mrosewski I, Mantel V, Urbank M, Schulze-Tanzil G, Werner C, Gogele C Heliyon. 2024; 10(23):e40826.

PMID: 39719993 PMC: 11666950. DOI: 10.1016/j.heliyon.2024.e40826.


Animal models for type 1 and type 2 diabetes: advantages and limitations.

Singh R, Gholipourmalekabadi M, Shafikhani S Front Endocrinol (Lausanne). 2024; 15:1359685.

PMID: 38444587 PMC: 10912558. DOI: 10.3389/fendo.2024.1359685.


Affective and Cognitive Impairments in Rodent Models of Diabetes.

Palazzo E, Marabese I, Boccella S, Belardo C, Pierretti G, Maione S Curr Neuropharmacol. 2024; 22(8):1327-1343.

PMID: 38279738 PMC: 11092917. DOI: 10.2174/1570159X22666240124164804.


Increased Frequency of Giant Miniature End-Plate Potentials at the Neuromuscular Junction in Diabetic Rats.

Martinez-Sanchez J, Cardenas Y, Trujillo X, Rios-Silva M, Diaz-Reval M, Bricio-Barrios J Biomedicines. 2024; 12(1).

PMID: 38255175 PMC: 10813272. DOI: 10.3390/biomedicines12010068.


Non-Genetic-Induced Zebrafish Model for Type 2 Diabetes with Emphasis on Tools in Model Validation.

Sanni O, Fasemore T, Nkomozepi P Int J Mol Sci. 2024; 25(1).

PMID: 38203409 PMC: 10778736. DOI: 10.3390/ijms25010240.


References
1.
Rees D, Alcolado J . Animal models of diabetes mellitus. Diabet Med. 2005; 22(4):359-70. DOI: 10.1111/j.1464-5491.2005.01499.x. View

2.
Chehab F, Lim M, Lu R . Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet. 1996; 12(3):318-20. DOI: 10.1038/ng0396-318. View

3.
Derscheid R, Ackermann M . Perinatal lamb model of respiratory syncytial virus (RSV) infection. Viruses. 2012; 4(10):2359-78. PMC: 3497056. DOI: 10.3390/v4102359. View

4.
Koch J, Tatenhorst L, Roser A, Saal K, Tonges L, Lingor P . ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol Ther. 2018; 189:1-21. DOI: 10.1016/j.pharmthera.2018.03.008. View

5.
Zhao M, Lepak A, Andes D . Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Bioorg Med Chem. 2016; 24(24):6390-6400. DOI: 10.1016/j.bmc.2016.11.008. View